These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 27821322)

  • 1. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
    Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
    Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
    Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
    Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR; Ruggiero A; Lucidi D; De Corso E; Sergi B; Conti G; Paludetti G
    Audiol Neurootol; 2016; 21(4):203-211. PubMed ID: 27286730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of hearing loss after platinum chemotherapy in childhood cancer survivors.
    Strebel S; Mader L; Sláma T; Waespe N; Weiss A; Parfitt R; Am Zehnhoff-Dinnesen A; Kompis M; von der Weid NX; Ansari M; Kuehni CE
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29755. PubMed ID: 35723448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
    Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
    Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
    Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
    J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.
    Kooijmans EC; Bökenkamp A; Tjahjadi NS; Tettero JM; van Dulmen-den Broeder E; van der Pal HJ; Veening MA
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008944. PubMed ID: 30855726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Chuang A; Del Valle Á; Cordova M
    Int J Pediatr Otorhinolaryngol; 2018 Apr; 107():75-79. PubMed ID: 29501316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity monitoring in children treated with platinum chemotherapy.
    Brooks B; Knight K
    Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
    Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
    J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
    Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
    Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.